ALG3 Congenital Disorder of Glycosylation (ALG3-CDG)

Dr. Nadia Falah, MD - Clinical Genetics, Genomics, Cytogenetics, Biochemical Genetics Specialist Dr. Nadia Falah, MD - Clinical Genetics, Genomics, Cytogenetics, Biochemical Genetics Specialist
19 Views
Rx Autoimmune, Genetic and Rare Diseases (A - Z)

ALG3-CDG is a rare, inherited metabolic disease. It happens when a child receives two faulty copies of the ALG3 gene (one from each parent). The ALG3 gene makes an enzyme that adds a sugar unit (mannose) onto a growing sugar chain while the body builds N-linked glycans. These glycans are tiny sugar “labels” that help many proteins fold, travel, and work properly. When ALG3 is not working, proteins are made with the wrong sugar pattern. This affects many body systems, especially the brain and nerves, and can lead to low muscle tone (hypotonia), developmental delay, seizures (often hard to control), small head size after birth (postnatal microcephaly), vision problems, and sometimes liver and growth problems. There is no cure yet. Care is supportive and multidisciplinary. cdghub.com+2rarediseases.info.nih.gov+2

ALG3-CDG is a very rare, inherited, multi-system disease. It starts in early life. The main problems happen in the brain and nervous system, but other organs can be involved too. The condition occurs because a gene called ALG3 does not work properly. This gene gives instructions to make an enzyme (alpha-1,3-mannosyltransferase) that adds a sugar unit to growing N-glycans inside the cell’s endoplasmic reticulum. When the enzyme is missing or weak, many body proteins do not get the correct sugar chains. Such under-glycosylated proteins cannot fold, traffic, or function normally. This leads to low muscle tone (hypotonia), severe developmental delay, seizures (often early and hard to control), small head size after birth (postnatal microcephaly), and sometimes eye, face, bone, heart, kidney, and immune problems. ALG3-CDG is autosomal recessive, meaning a child is affected when they inherit one non-working copy of ALG3 from each parent. NCBI+3Orpha+3rarediseases.info.nih.gov+3

Other names

  • ALG3-CDG

  • Congenital disorder of glycosylation, type Id (older name: CDG-Id)

  • Alpha-1,3-mannosyltransferase deficiency

  • ALG3 deficiency
    These terms all refer to the same disease caused by disease-causing variants in ALG3 on chromosome 3q27.3. rarediseases.info.nih.gov+1

How the disease happens

Inside every cell, many proteins need sugar chains (called glycans) attached to work correctly. These chains are built step-by-step on a “lipid handle” (dolichol) in the endoplasmic reticulum. ALG3 controls one early step: adding a mannose sugar in an alpha-1,3 link to a five-mannose core (Man_5GlcNAc_2-PP-Dol) to make Man_6GlcNAc_2-PP-Dol. If ALG3 is not working, this step is blocked. Intermediates build up, and many proteins leave the ER with too few sugars or wrong sugars (“type I” N-glycosylation defect). Cells throughout the body—especially brain cells—struggle to signal, connect, and survive. That broad failure explains the early seizures, profound developmental delay, visual impairment, and other organ problems. ScienceDirect+1

Types

Formal clinical subtypes have not been universally established because ALG3-CDG is very rare. In practice, doctors often think in terms of severity and timing:

  1. Early-infantile severe form (most reported cases): early hypotonia, feeding difficulties, severe global developmental delay, early epileptic encephalopathy (including infantile spasms/West syndrome), acquired microcephaly, and progressive brain atrophy. This group often has eye findings and facial/bony features. rarediseases.info.nih.gov+1

  2. Intermediate childhood form (less common): similar problems but seizures may be somewhat more manageable; limited developmental progress is possible.

  3. Very rare milder survivors: a few reports describe individuals with longer survival and partial skills, but neurological disability remains significant. (Because published numbers are small, true frequency of each pattern is uncertain.) Wiley Online Library

Causes

For a genetic disorder like ALG3-CDG, the root cause is biallelic (two-copy) pathogenic variants in ALG3. The items below describe biological mechanisms that cause or contribute to the signs and complications seen in affected children.

  1. Biallelic pathogenic variants in ALG3 (missense, nonsense, splice, frameshift) → loss or major reduction of alpha-1,3-mannosyltransferase activity; this is the fundamental cause. PubMed+1

  2. Block in early N-glycan assembly at the Man_5→Man_6 step → under-glycosylated glycoproteins throughout the body. ScienceDirect

  3. ER quality-control stress because mis-glycosylated proteins misfold → triggers cellular stress pathways and can impair cell survival, especially in neurons. NCBI

  4. Synaptic dysfunction because membrane receptors and ion channels need proper glycans → contributes to seizures and developmental encephalopathy. NCBI

  5. Abnormal brain development (neurogenesis and connectivity need glycoproteins) → microcephaly and delayed milestones. rarediseases.info.nih.gov

  6. Impaired cell-adhesion molecules (e.g., integrins) → affects brain wiring, muscle tone, and organ structure. NCBI

  7. Defective glycoprotein hormones and receptors → feeding problems, growth issues, and endocrine dysregulation in some CDGs. NCBI

  8. Coagulation factor under-glycosylation → can alter clotting tests (PT/aPTT) in CDGs, raising bleeding/bruising risk in some patients. NCBI

  9. Glycosylation-dependent immune pathways → recurrent infections arise in some patients. Rare Diseases Clinical Research Network

  10. Abnormal retinal/optic pathways (glycoproteins in photoreceptors and optic nerve myelination) → vision problems and cortical visual impairment. Rare Diseases Clinical Research Network

  11. Skeletal matrix glycoprotein changes → dysmorphic features, contractures, camptodactyly reported in ALG3-CDG. PMC

  12. Cardiac glycoprotein dysfunction → some CDG types show cardiomyopathy or rhythm issues; ALG3-CDG cohorts include heart involvement. Rare Diseases Clinical Research Network

  13. Renal tubular glycoprotein defects → kidney/uro-genital anomalies in some patients. Rare Diseases Clinical Research Network

  14. Hearing pathway involvement → sensorineural hearing loss reported. Rare Diseases Clinical Research Network

  15. Cerebellar and cerebral atrophy progression → contributes to motor and coordination difficulties. rarediseases.info.nih.gov

  16. Poor autonomic regulation via mis-glycosylated receptors → feeding intolerance, reflux, and temperature instability in infants with CDG. NCBI

  17. Respiratory vulnerability (weak cough, aspiration risk from hypotonia) → recurrent chest infections. Rare Diseases Clinical Research Network

  18. Energy and mitochondrial stress secondary to ER burden → fatigue, low stamina, and poor growth. NCBI

  19. Seizure propagation networks strengthened by glycan-related synaptic imbalance → early, often refractory epilepsy. PMC

  20. Global “systems” impact of under-glycosylation → because thousands of proteins require N-glycans, multiple organs are affected at once, explaining the wide symptom range. NCBI

Symptoms

  1. Severe developmental delay: slow or absent head control, sitting, speech. This is usually obvious in the first year. Orpha

  2. Low muscle tone (hypotonia): “floppy” feel, poor suck, and joint laxity early in life. Orpha

  3. Seizures: often begin in infancy and may include infantile spasms/West syndrome or other epileptic encephalopathies; seizures can be resistant to medicines. rarediseases.info.nih.gov+1

  4. Postnatal microcephaly: head growth falls off after birth as brain growth lags. rarediseases.info.nih.gov

  5. Progressive brain and cerebellar atrophy on MRI, matching loss of skills or slow gains. rarediseases.info.nih.gov

  6. Eye problems: poor visual tracking, cortical visual impairment, strabismus; some have structural eye findings. PMC+1

  7. Distinct facial features: broad/flat nasal bridge, thin upper lip, low-set ears, high-arched palate, micrognathia (details vary). PMC

  8. Skeletal and joint issues: camptodactyly (bent fingers), contractures, scoliosis in some. PMC

  9. Feeding problems and failure to thrive: difficulty coordinating suck/swallow, reflux, vomiting; slow weight gain. (Common across CDGs.) NCBI

  10. Recurrent infections: especially respiratory, linked to weakness, aspiration risk, and immune effects. Rare Diseases Clinical Research Network

  11. Hearing loss: often sensorineural. Rare Diseases Clinical Research Network

  12. Breathing/respiratory issues: aspiration, weak cough, and infection-related complications. Rare Diseases Clinical Research Network

  13. Heart involvement: some children show structural or rhythm issues. Rare Diseases Clinical Research Network

  14. Kidney/urogenital anomalies: variable; may be detected on ultrasound or due to recurrent UTIs. Rare Diseases Clinical Research Network

  15. Global disability: most children need full support for mobility, feeding, and daily care over time. Orpha

Diagnostic tests

Doctors suspect ALG3-CDG when a baby or child has severe hypotonia, early hard-to-control seizures, acquired microcephaly, and multi-system signs. Screening looks for type I transferrin patterns (a hallmark of N-glycosylation assembly defects) and then confirms by genetic testing of the ALG3 gene. Additional tests map how organs are affected and guide day-to-day care. NCBI+1

A) Physical-exam based (bedside observations)

  1. General neurologic exam: documents tone, reflexes, head size, head growth curve, and developmental level. These findings raise suspicion and set the baseline for care. Orpha

  2. Dysmorphology exam: notes facial shape, palate, jaw, ear position, fingers/toes, contractures—clues that suggest a glycosylation disorder pattern. PMC

  3. Growth and nutrition assessment: tracks weight, length, head circumference, and feeding tolerance to plan nutrition support. (Growth issues are common across CDGs.) NCBI

  4. Vision assessment at bedside: fixation and tracking checks; referral if poor visual behavior suggests cortical visual impairment or eye disease. Rare Diseases Clinical Research Network

  5. Cardiorespiratory exam: listens for murmurs, checks breathing effort, and looks for recurrent chest infections or aspiration signs. Rare Diseases Clinical Research Network

B) Manual/functional tests (simple clinic procedures)

  1. Standardized developmental testing (e.g., Bayley or similar): measures cognitive, language, and motor skills to monitor progress and therapy needs over time. NCBI

  2. Ophthalmology slit-lamp and fundus exam: searches for strabismus, optic issues, or retinal findings that occur in CDGs. PMC

  3. Audiology (otoacoustic emissions/behavioral testing): screens for hearing loss so that early supports can be provided. Rare Diseases Clinical Research Network

C) Laboratory & pathological tests (core to diagnosis)

  1. Serum transferrin isoelectric focusing (TIEF): a classic screen for type I CDG pattern (fewer sialic acids on transferrin), which points to an early N-glycan assembly defect like ALG3-CDG. NCBI

  2. Transferrin glycoform analysis by LC-MS: a more precise way to detect and quantify abnormal transferrin glycoforms; often used as a modern alternative or add-on to TIEF. NCBI

  3. Plasma/serum N-glycan profiling (MALDI-TOF or LC-MS): shows the build-up of undersized glycans consistent with an ALG3 pathway block. NCBI

  4. Molecular genetic testing of ALG3 (gene panel, exome, or genome): confirms the diagnosis by finding disease-causing variants in both copies of the gene. This is the definitive test. cdghub.com+1

  5. Enzyme/functional studies in fibroblasts (specialized centers): can demonstrate reduced alpha-1,3-mannosyltransferase activity or ER glycan intermediates; used mainly in research or complex cases. ScienceDirect

  6. Liver function and coagulation tests (AST/ALT, PT/aPTT, antithrombin): some CDG patients show liver and clotting abnormalities that affect procedures and safety planning. NCBI

  7. Endocrine labs (thyroid function, IGF-1, others as indicated): screens for hormone issues that can worsen growth and development if untreated. NCBI

  8. Immune studies (immunoglobulins, vaccine titers when appropriate): helps explain recurrent infections and directs prophylaxis or therapy. Rare Diseases Clinical Research Network

D) Electrodiagnostic tests

  1. Electroencephalogram (EEG): defines seizure type and severity; in infants may show hypsarrhythmia in those with infantile spasms/West syndrome. Guides anti-seizure therapy and dietary therapy (e.g., ketogenic diet). PMC+1

  2. Evoked potentials (visual and auditory): evaluate pathway conduction when eye or hearing concerns are present. Helpful in nonverbal children. NCBI

E) Imaging tests

  1. Brain MRI (with attention to cerebrum and cerebellum): commonly shows progressive atrophy and white-matter or cortical changes that support a CDG diagnosis in the right clinical setting. rarediseases.info.nih.gov

  2. Targeted organ imaging as needed: echocardiogram (heart), renal ultrasound (kidneys/urinary tract), spine films for scoliosis or contractures—these define the extent of multi-organ involvement and guide management. Rare Diseases Clinical Research Network

Non-pharmacological treatments

  1. Early intervention therapies: start physio/OT/speech as soon as possible to build motor, feeding, and communication skills; uses neuroplasticity (the brain’s ability to learn). BioMed Central

  2. Physiotherapy: posture, strength, contracture prevention; improves movement by repeated, guided practice. BioMed Central

  3. Occupational therapy: feeding, hand use, daily skills; adapts tasks and environments to the child’s abilities. BioMed Central

  4. Speech-language therapy: oral-motor skills, swallowing safety, alternative communication; trains muscles and introduces AAC devices if needed. ScienceDirect

  5. Feeding therapy & texture modification: reduces aspiration and improves calories; changes food thickness and posture at meals. ScienceDirect

  6. High-calorie nutrition plan: prevents malnutrition and supports growth; small, frequent, energy-dense feeds. ScienceDirect

  7. Ketogenic diet (for refractory epilepsy): medical, high-fat diet that shifts brain fuel to ketones; may reduce seizures (case-level evidence in ALG3-CDG). Must be supervised. ScienceDirect

  8. Vision rehabilitation: glasses, patching, low-vision tools; enhances remaining vision pathways. PMC

  9. Seizure first-aid training for caregivers: safety during events; lowers injury risk. BioMed Central

  10. Sleep hygiene routine: consistent schedule, dark/quiet room; supports brain recovery and behavior. BioMed Central

  11. Respiratory physiotherapy: airway clearance techniques when weak cough/aspiration; reduces infections. AAP Publications

  12. Positioning/orthoses: seating systems, ankle-foot orthoses; improves alignment and prevents deformities. BioMed Central

  13. Communication aids (AAC): signs, pictures, devices; lets the child express needs earlier, reducing frustration. BioMed Central

  14. Special education plan (IEP): structured goals at school; ensures therapy continues in the classroom. BioMed Central

  15. Infection-prevention practices: hand hygiene, vaccines, prompt care; reduces illness-related setbacks. BioMed Central

  16. Gastrostomy (G-tube) feeding support as a non-drug nutritional intervention: reliable calories and safer hydration when aspiration is high. ScienceDirect

  17. Behavioral strategies: routines and positive reinforcement; help coping with irritability or sensory issues. BioMed Central

  18. Social work and caregiver support: helps with equipment, transport, therapy scheduling; lowers family stress. BioMed Central

  19. Palliative care involvement (alongside active care): symptom relief, goals of care, support for complex decisions. BioMed Central

  20. Regular multidisciplinary reviews: neurology, genetics, nutrition, physiatry, ophthalmology, gastroenterology; anticipates complications and updates the plan. BioMed Central

Drug treatments

Always individualized by a clinician. Ranges are typical pediatric references, not prescriptions.

Seizure control (choose based on EEG/type):

  1. Levetiracetam (AED): ~20–60 mg/kg/day in 2 doses. Daily. Purpose: broad seizure control; Mechanism: SV2A modulation; Side effects: irritability, somnolence. BioMed Central

  2. Valproate (AED): ~10–60 mg/kg/day in divided doses. Purpose: generalized seizures; Mechanism: GABA effects; Side effects: liver toxicity, thrombocytopenia—caution if liver disease. BioMed Central

  3. Topiramate (AED): ~5–10 mg/kg/day divided. Purpose: adjunct for refractory epilepsy; Mechanism: sodium channel/GABA; Side effects: appetite loss, acidosis, stones. BioMed Central

  4. Vigabatrin (AED, esp. infantile spasms with tuberous sclerosis; sometimes tried): ~50–150 mg/kg/day divided. Mechanism: GABA transaminase inhibition; Side effects: visual field loss risk (ophthalmic monitoring). BioMed Central

  5. ACTH or oral steroids (for infantile spasms): dosing per protocol; Purpose: stop spasms; Mechanism: corticotropic pathways; Side effects: hypertension, infection risk. BioMed Central

  6. Rescue benzodiazepines (diazepam/lorazepam/buccal midazolam): per weight-based emergency plan; Purpose: stop prolonged seizures; Side effects: sedation, respiratory depression. BioMed Central

Tone, spasticity, and comfort:

  1. Baclofen (antispastic): ~0.3–0.75 mg/kg/dose up to TID. Purpose: reduce spasticity; Mechanism: GABAB_B agonist; Side effects: sedation, hypotonia. BioMed Central
  2. Botulinum toxin (focal spasticity): injected every 3–6 months; Purpose: relax overactive muscles; Mechanism: blocks acetylcholine; Side effects: local weakness, rare dysphagia. BioMed Central

Feeding, reflux, constipation:

  1. Omeprazole (PPI): ~0.7–1 mg/kg/day. Purpose: reflux control; Mechanism: acid pump blockade; Side effects: GI upset, low magnesium with long use. ScienceDirect
  2. Domperidone/metoclopramide (prokinetics, where available/appropriate): weight-based; Purpose: improve gastric emptying; Side effects: cardiac/QT or extrapyramidal risks—use cautiously. ScienceDirect
  3. Polyethylene glycol (osmotic laxative): ~0.4–1 g/kg/day. Purpose: treat constipation; Side effects: bloating. ScienceDirect

Sialorrhea, sleep, behavior (symptom relief):

  1. Glycopyrrolate (anti-saliva): ~0.02 mg/kg/dose TID. Purpose: reduce drooling/aspiration; Side effects: dry mouth, constipation. BioMed Central
  2. Melatonin: ~1–5 mg at bedtime. Purpose: sleep regulation; Side effects: morning drowsiness. BioMed Central

Nutrition and mitochondrial support (empirical in CDG):

  1. L-carnitine: ~50–100 mg/kg/day divided. Purpose: fatty-acid transport if low intake; Side effects: fishy odor, GI upset. BioMed Central
  2. Coenzyme Q10: ~5–10 mg/kg/day. Purpose: antioxidant/mitochondrial support (empirical); Side effects: GI upset. Frontier
  3. Riboflavin (B2): ~10–50 mg/day. Purpose: cofactor support (empirical); Side effects: harmless yellow urine. Frontiers
  4. Thiamine (B1): ~10–50 mg/day. Purpose: energy metabolism support; Side effects: rare. Frontiers
  5. Pyridoxine (B6) trial: per protocol; monitor for neuropathy at high doses. Sometimes tried in refractory epilepsy; Side effects: sensory neuropathy if excessive. BioMed Central

General pediatric safety meds (as needed):

  1. Antipyretics (acetaminophen/ibuprofen): weight-based; Purpose: fever comfort; Side effects: liver (acetaminophen overdose), GI/renal (ibuprofen). BioMed Central
  2. Antibiotics per infection and culture: Purpose: treat bacterial infections promptly to avoid decompensation; Side effects: drug-specific. BioMed Central

Note: Some CDG subtypes have disease-specific treatments (e.g., mannose for MPI-CDG), but ALG3-CDG does not have a proven disease-modifying drug at this time. Management is supportive and symptom-targeted. Frontiers+1

Dietary molecular supplements

These are adjuncts used empirically in CDG care when appropriate. Always check with the metabolic team.

  1. Coenzyme Q10 (5–10 mg/kg/day): mitochondrial antioxidant; supports electron transport. Frontiers

  2. L-carnitine (50–100 mg/kg/day): transports long-chain fatty acids into mitochondria; may aid energy if low. BioMed Central

  3. Riboflavin B2 (10–50 mg/day): cofactor for flavoproteins; may help energy metabolism. Frontiers

  4. Thiamine B1 (10–50 mg/day): cofactor in carbohydrate metabolism; supports ATP production. Frontiers

  5. Pyridoxine B6 (per protocol): neurotransmitter synthesis; sometimes reduces seizures in selected patients. BioMed Central

  6. Biotin (5–10 mg/day): carboxylase cofactor; general metabolic support. BioMed Central

  7. Vitamin D (per level-guided dosing): bone and immune support; prevents deficiency. BioMed Central

  8. Omega-3 fatty acids (EPA/DHA per weight): anti-inflammatory; possible neurocognitive support. BioMed Central

  9. Magnesium (per age/weight): muscle/nerve function; may aid sleep/constipation. BioMed Central

  10. Alpha-lipoic acid (age-appropriate dosing): antioxidant; supports redox balance. Frontiers

Regenerative / stem-cell drugs

At present, there are no validated “immunity-booster,” “regenerative,” or “stem-cell” drugs for ALG3-CDG. Hematopoietic stem-cell transplant and gene therapy are research concepts, not standard care for ALG3-CDG. Some CDG guidelines discuss future strategies like enzyme enhancement, chaperones, or gene-targeted approaches, but these are experimental and not prescribed clinically for ALG3-CDG today. Because they are unproven, dosage cannot be recommended. Safer immune support focuses on routine vaccines, nutrition, prompt infection treatment, and, in rare immune-deficient cases, clinician-directed therapies (e.g., IVIG) based on tests. Frontiers+1

Surgeries or procedures

  1. Gastrostomy tube (G-tube) placement: for unsafe swallow or poor intake; ensures safe calories and medications. ScienceDirect

  2. Fundoplication (selected cases): for severe reflux not controlled by meds; reduces aspiration risk. ScienceDirect

  3. Orthopedic surgery (e.g., hip reduction, scoliosis procedures): to prevent pain/deformity and improve seating, hygiene, and function. BioMed Central

  4. Strabismus surgery or ocular procedures: to improve alignment or treat complications and support vision function. PMC

  5. Airway procedures (e.g., tracheostomy) in exceptional cases: for chronic aspiration/airway protection when conservative care fails. AAP Publications

Preventions

  1. Carrier testing and genetic counseling for parents and adult relatives. cdghub.com

  2. Prenatal or preimplantation genetic testing in future pregnancies when desired. BioMed Central

  3. Complete routine vaccinations (and influenza/COVID as advised) to reduce infections. BioMed Central

  4. Hand hygiene and infection control at home and school. BioMed Central

  5. Texture-modified feeds and swallow strategies to prevent aspiration. ScienceDirect

  6. Nutrition plans to prevent malnutrition and pressure sores. ScienceDirect

  7. Physiotherapy and stretching to prevent contractures and scoliosis. BioMed Central

  8. Seizure action plan (rescue meds available) to prevent prolonged seizures/injury. BioMed Central

  9. Regular vision and hearing checks to prevent avoidable disability. PMC

  10. Multidisciplinary follow-up to catch complications early. BioMed Central

When to see a doctor urgently

  • New or worsening seizures, prolonged seizures, or first seizure.

  • Feeding problems with coughing, choking, or weight loss.

  • Signs of dehydration, persistent vomiting, or severe constipation.

  • Breathing trouble, repeated chest infections, or blue lips/skin.

  • Sudden change in alertness, weakness, or behavior.

  • Fever with poor intake or lethargy.

  • Eye problems (new squint, rapid vision change).

  • Any concern that “something is not right.” AAP Publications+1

What to eat and what to avoid

What to eat:

  • Energy-dense foods (add oils, nut butters if safe; or prescribed formulas) to support growth.

  • Adequate protein and balanced carbs/fats; small, frequent meals.

  • Texture-modified foods and thickened liquids if advised by the swallow team.

  • Hydration plan (water, oral rehydration solutions when ill).

  • Micronutrient-rich foods (iron, calcium, vitamin D, etc.) and supplements when prescribed. ScienceDirect

What to avoid:

  • Thin liquids or unsafe textures if aspiration risk is present.

  • Fasting or long gaps between meals (can worsen weakness or irritability).

  • Unsupervised “miracle” supplements or stem-cell products advertised online.

  • Hepatotoxic drugs without medical oversight, especially if liver involvement (e.g., use valproate cautiously). ScienceDirect+1

Frequently asked questions (FAQs)

1) What causes ALG3-CDG?
Biallelic harmful changes in the ALG3 gene disrupt a key step in N-glycosylation, so many proteins do not get the right sugar chains. NCBI+1

2) How is it inherited?
Autosomal recessive: parents are usually healthy carriers; each pregnancy has a 25% chance of an affected child. cdghub.com

3) How common is it?
Very rare; only a few dozen cases reported, though diagnosis is increasing with modern testing. cdghub.com

4) What are the main symptoms?
Developmental delay, hypotonia, seizures (often early/refractory), microcephaly, feeding issues, visual problems. rarediseases.info.nih.gov+1

5) How is it diagnosed?
CDG screening by transferrin glycoforms plus genetic testing that finds variants in ALG3. NCBI+1

6) Is there a cure?
No disease-specific cure yet; care is supportive, focused on symptoms and quality of life. Frontiers

7) Are there treatments that help seizures?
Yes. Standard antiseizure medicines and, in selected refractory cases, a ketogenic diet under specialist care. ScienceDirect

8) Do vitamins or supplements help?
No supplement fixes ALG3, but some clinicians consider CoQ10, carnitine, B-vitamins as supportive in CDG. Decisions are individualized. Frontiers

9) What about mannose therapy?
Mannose helps MPI-CDG, not ALG3-CDG. It is not a proven therapy for ALG3. Frontiers

10) Can children improve?
With early therapies, nutrition, and seizure control, many children gain skills and comfort, but challenges often remain. BioMed Central

11) What specialists are involved?
Neurology, genetics, gastroenterology/nutrition, physiatry, ophthalmology, physiotherapy/OT/speech, and social work. BioMed Central

12) Are vaccines safe?
Routine vaccines are recommended unless a doctor advises otherwise for a specific reason. Preventing infections is very important. BioMed Central

13) What tests follow over time?
Growth, development, seizure control, swallow safety, liver tests as needed, vision/hearing, and nutritional status. BioMed Central

14) Should families get genetic counseling?
Yes. It explains inheritance, carrier testing, and options for future pregnancies. BioMed Central

15) Where can I find trustworthy information?
Look at Orphanet, NIH Genetic and Rare Diseases, CDG Hub, and peer-reviewed reviews/guidelines listed below. Orpha+2rarediseases.info.nih.gov+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 12, 2025.

PDF Documents For This Disease Condition

  1. Rare Diseases and Medical Genetics.[rxharun.com]
  2. i2023_IFPMA_Rare_Diseases_Brochure_28Feb2017_FINAL.[rxharun.com]
  3. the-UK-rare-diseases-framework.[rxharun.com]
  4. National-Recommendations-for-Rare-Disease-Health-Care-Summary.[rxharun.com]
  5. History of rare diseases and their genetic.[rxharun.com]
  6. health-care-and-rare-disorders.[rxharun.com]
  7. Rare Disease Registries.[rxharun.com]
  8. autoimmune-Rare-Genetic-Diseases.[rxharun.com]
  9. Rare Genetic Diseases.[rxharun.com]
  10. rare-disease-day.[rxharun.com]
  11. Rare_Disease_Drugs_e.[rxharun.com]
  12. fda-CDER-Rare-Diseases-Public-Workshop-Master.[rxharun.com]
  13. rare-and-inherited-disease-eligibility-criteria.[rxharun.com]
  14. FDA-rare-disease-list.pdf-rxharun.com1 Human-Gene-Therapy-for-Rare Diseases_Jan_2020fda.[rxharun.com]
  15. FDA-rare-disease-lists.[rxharun.com]
  16. 30212783fnl_Rare Disease.[rxharun.com]
  17. FDA-rare-disease-list.[rxharun.com]
  18. List of rare disease.[rxharun.com]
  19. Genome Res.-2025-Steyaert-755-68.[rxharun.com]
  20. uk-practice-guidelines-for-variant-classification-v4-01-2020.[rxharun.com]
  21. PIIS2949774424010355.[rxharun.com]
  22. hidden-costs-2016.[rxharun.com]
  23. B156_CONF2-en.[rxharun.com]
  24. IRDiRC_State-of-Play-2018_Final.[rxharun.com]
  25. IRDR_2022Vol11No3_pp96_160.[rxharun.com]
  26. from-orphan-to-opportunity-mastering-rare-disease-launch-excellence.[rxharun.com]
  27. Rare disease fda.[rxharun.com]
  28. England-Rare-Diseases-Action-Plan-2022.[rxharun.com]
  29. SCRDAC 2024 Report.[rxharun.com]
  30. CORD-Rare-Disease-Survey_Full-Report_Feb-2870-2.[rxharun.com]
  31. Stats-behind-the-stories-Genetic-Alliance-UK-2024.[rxharun.com]
  32. rare-and-inherited-disease-eligibility-criteria-v2.[rxharun.com]
  33. ENG_White paper_A4_Digital_FINAL.[rxharun.com]
  34. UK_Strategy_for_Rare_Diseases.[rxharun.com]
  35. MalaysiaRareDiseaseList.[rxharun.com]
  36. EURORDISCARE_FULLBOOKr.[rxharun.com]
  37. EMHJ_1999_5_6_1104_1113.[rxharun.com]
  38. national-genomic-test-directory-rare-and-inherited-disease-eligibilitycriteria-.[rxharun.com]
  39. be-counted-052722-WEB.[rxharun.com]
  40. RDI-Resource-Map-AMR_MARCH-2024.[rxharun.com]
  41. genomic-analysis-of-rare-disease-brochure.[rxharun.com]
  42. List-of-rare-diseases.[rxharun.com]
  43. RDI-Resource-Map-AFROEMRO_APRIL[rxharun.com]
  44. rdnumbers.[rxharun.com] .
  45. Rare disease atoz .[rxharun.com]
  46. EmanPublisher_12_5830biosciences-.[rxharun.com]

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK208609/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6279436/
  3. https://rarediseases.org/rare-diseases/
  4. https://rarediseases.info.nih.gov/diseases
  5. https://en.wikipedia.org/w/index.php?title=Category:Rare_diseases
  6. https://en.wikipedia.org/wiki/List_of_genetic_disorders
  7. https://en.wikipedia.org/wiki/Category:Genetic_diseases_and_disorders
  8. https://medlineplus.gov/genetics/condition/
  9. https://geneticalliance.org.uk/support-and-information/a-z-of-genetic-and-rare-conditions/
  10. https://www.fda.gov/patients/rare-diseases-fda
  11. https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/support-clinical-trials-advancing-rare-disease-therapeutics-start-pilot-program
  12. https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/jcph.2134
  13. https://www.mayoclinicproceedings.org/article/S0025-6196%2823%2900116-7/fulltext
  14. https://www.ncbi.nlm.nih.gov/mesh?
  15. https://www.rarediseasesinternational.org/working-with-the-who/
  16. https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03322-7
  17. https://www.rarediseasesnetwork.org/
  18. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/rare-disease
  19. https://www.raregenomics.org/rare-disease-list
  20. https://www.astrazeneca.com/our-therapy-areas/rare-disease.html
  21. https://bioresource.nihr.ac.uk/rare
  22. https://www.roche.com/solutions/focus-areas/neuroscience/rare-diseases
  23. https://geneticalliance.org.uk/support-and-information/a-z-of-genetic-and-rare-conditions/
  24. https://www.genomicsengland.co.uk/genomic-medicine/understanding-genomics/rare-disease-genomics
  25. https://www.oxfordhealth.nhs.uk/cit/resources/genetic-rare-disorders/
  26. https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-022-01026
  27. https://wikicure.fandom.com/wiki/Rare_Diseases
  28. https://www.wikidoc.org/index.php/List_of_genetic_disorders
  29. https://www.medschool.umaryland.edu/btbank/investigators/list-of-disorders/
  30. https://www.orpha.net/en/disease/list
  31. https://www.genetics.edu.au/SitePages/A-Z-genetic-conditions.aspx
  32. https://ojrd.biomedcentral.com/
  33. https://health.ec.europa.eu/rare-diseases-and-european-reference-networks/rare-diseases_en
  34. https://bioportal.bioontology.org/ontologies/ORDO
  35. https://www.orpha.net/en/disease/list
  36. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions
  37. https://www.gao.gov/products/gao-25-106774
  38. https://www.gene.com/partners/what-we-are-looking-for/rare-diseases
  39. https://www.genome.gov/For-Patients-and-Families/Genetic-Disorders
  40. https://geneticalliance.org.uk/support-and-information/a-z-of-genetic-and-rare-conditions/
  41. https://my.clevelandclinic.org/health/diseases/21751-genetic-disorders
  42. https://globalgenes.org/rare-disease-facts/
  43. https://www.nidcd.nih.gov/directory/national-organization-rare-disorders-nord
  44. https://byjus.com/biology/genetic-disorders/
  45. https://www.cdc.gov/genomics-and-health/about/genetic-disorders.html
  46. https://www.genomicseducation.hee.nhs.uk/doc-type/genetic-conditions/
  47. https://www.thegenehome.com/basics-of-genetics/disease-examples
  48. https://www.oxfordhealth.nhs.uk/cit/resources/genetic-rare-disorders/
  49. https://www.pfizerclinicaltrials.com/our-research/rare-diseases
  50. https://clinicaltrials.gov/ct2/results?recrs
  51. https://apps.who.int/gb/ebwha/pdf_files/EB116/B116_3-en.pdf
  52. https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.21-0239
  53. https://www.nibib.nih.gov/
  54. https://www.nei.nih.gov/
  55. https://oxfordtreatment.com/
  56. https://www.nidcd.nih.gov/health/https://consumer.ftc.gov/articles/
  57. https://www.nccih.nih.gov/health
  58. https://catalog.ninds.nih.gov/
  59. https://www.aarda.org/diseaselist/
  60. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets
  61. https://www.nibib.nih.gov/
  62. https://www.nia.nih.gov/health/topics
  63. https://www.nichd.nih.gov/
  64. https://www.nimh.nih.gov/health/topics
  65. https://www.nichd.nih.gov/
  66. https://www.niehs.nih.gov/
  67. https://www.nimhd.nih.gov/
  68. https://www.nhlbi.nih.gov/health-topics
  69. https://obssr.od.nih.gov/.
  70. https://www.nichd.nih.gov/health/topics
  71. https://rarediseases.info.nih.gov/diseases
  72. https://beta.rarediseases.info.nih.gov/diseases
  73. https://orwh.od.nih.gov/

 

Related Articles

No widgets added. You can disable footer widget area in theme options - footer options

RxHarun
Logo